|
FLOMAX - GENERIC
generic name: tamsulosin
|
 |
| |
 |
Reviews |
|
Flomax - generic |
Eur Urol. 2005 Mar;47(3):361-5. Epub
2004 Dec 16.
The utility of tamsulosin in
the management of orgasm-associated pain: a pilot analysis.
Barnas J, Parker M, Guhring P, Mulhall JP.
Department of Urology, Weill Medical College of Cornell University,
New York Presbyterian Hospital, 525 E 68th Street, Starr 900, NY 10021,
USA.
INTRODUCTION:: Orgasmic pain is an infrequently reported but distressing
problem for the patients who experience it. No consensus exists as to its
etiology however bladder neck/pelvic floor spasm may play a role. This analysis
was conducted to assess the effect of the alpha-blocking medication, tamsulosin
on post-orgasmic pain. METHODS:: In a prospective, non-placebo controlled
study, patients with orgasmic pain were interviewed and administered tamsulosin
0.4mg po qhs for at least 4 weeks. Outcome measures included libido, pain
and continence and these were evaluated using the International Index of
Erectile Function (IIEF), a visual analog scale (VAS) for pain and an incontinence
scale respectively pre and post treatment. Patients were separated into
groups based on etiology of the problem (radical prostatectomy, radiation
therapy, and other) for statistical analysis. RESULTS:: 98 patients were
enrolled. Pain was located predominantly in the penis (72%), with other
sites including testis, rectum and abdomen. Most patients (52%) experienced
pain for less than 5minutes post-orgasm. 76/98 (77%) patients reported significant
improvement in pain (>/=2 points on pain VAS) and 12/98 (12%) noted complete
resolution of their pain. The VAS for pain reflected a statistically significant
decrease in pain for all groups in response to tamsulosin treatment. The
entire group had a decrease of 2.7 points between pre and post-treatment
phases. The IIEF libido domain increased significantly (mean of 2.4 points)
for all treatment groups. CONCLUSION:: Tamsulosin decreases orgasmic pain
intensity in patients with orgasmic pain. These data support the hypothesis
that orgasmic pain is related to bladder neck and/or pelvic floor muscle
spas. |
BJU Int. 2005 Feb;95(3):354-7.
Tamsulosin in the management of patients in
acute urinary retention from benign prostatic hyperplasia.
Lucas MG, Stephenson TP, Nargund V.
Morriston
Hospital, Swansea, UK. malcolm.lucas@swansea-tr.wales.
OBJECTIVE: To evaluate the efficacy of tamsulosin compared to placebo for
treating catheterized patients with acute urinary retention (AUR) caused
by benign prostatic hyperplasia (BPH), by comparing the numbers of patients
who voided successfully after removing their catheter. PATIENTS AND METHODS:
This was a randomized, double-blind, placebo-controlled, parallel-group,
multicentre study. Men with AUR secondary to BPH were catheterized and then,
if they fulfilled the entry criteria, were randomly assigned to receive
either 0.4 mg tamsulosin hydrochloride in a modified-release capsule once
daily, or a placebo. After up to eight doses the catheter was removed and
the ability to void unaided assessed. RESULTS: In all, 149 men (mean age
69.4 years) were randomly assigned to receive tamsulosin (75) or placebo
(74); eight were not evaluable, so the intent-to-treat population was 141
men. Thirty-four men taking tamsulosin and 18 taking placebo did not require
re-catheterization on the day of the trial without catheter (48% and 26%
respectively, P = 0.011; odds ratio 2.47, 95% confidence interval, CI, 1.23-4.97).
Success using free-flow variables was also higher in the men who received
tamsulosin, at 37 (52%) vs 24 (34%) on placebo (P = 0.019; odds ratio 2.34,
95% CI 1.15-4.75). Withdrawals were high (120 men, 81%), mostly because
of a need for re-catheterization (89 men, 60%). Dizziness and somnolence
occurred in seven (10%) and four (6%) men who received tamsulosin, and two
(3%) who received placebo, but overall the incidence of adverse events was
similar in the two groups. One patient died from carcinomatosis. CONCLUSION:
Men catheterized for AUR can void more successfully after catheter removal
if treated with tamsulosin, and are less likely to need re-catheterization.
The side-effect profile was similar for tamsulosin and placebo, and consistent
with known pharmacology. From these results tamsulosin can be recommended
for treating men after catheterization for AUR, and can reduce the likelihood
of the need for re-catheterization. |
Ann Intern Med. 2004 Oct 19;141(8):581-9.
Ciprofloxacin or tamsulosin in men with chronic
prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial.
Carbone DJ Jr, Hodges S.
Veterans Affairs
Maryland Health Care System and University of Maryland School of Medicine,
Baltimore, Maryland 21201, USA. ralexander@smail.umaryland.edu
BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in
men is principally defined by pain in the pelvic region lasting more than
3 months. No cause of the disease has been established, and therapies are
empirical and mostly untested. Antimicrobial agents and alpha-adrenergic
receptor blockers are frequently used. OBJECTIVE: To determine whether 6-week
therapy with ciprofloxacin or tamsulosin is more effective than placebo
at improving symptoms in men with refractory, long-standing CP/CPPS. DESIGN:
Randomized, double-blind trial with a 2 x 2 factorial design comparing 6
weeks of therapy with ciprofloxacin, tamsulosin, both drugs, or placebo.
SETTING: Urology outpatient clinics at 10 tertiary care medical centers
in North America. PATIENTS: Patients were identified from referral-based
practices of urologists. One hundred ninety-six men with a National Institutes
of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score of at least
15 and a mean of 6.2 years of symptoms were enrolled. Patients had received
substantial previous treatment. MEASUREMENTS: The authors evaluated NIH-CPSI
total score and subscores, patient-reported global response assessment,
a generic measure of quality of life, and adverse events. Interventions:
Ciprofloxacin, 500 mg twice daily; tamsulosin, 0.4 mg once daily; a combination
of the 2 drugs; or placebo. RESULTS: The NIH-CPSI total score decreased
modestly in all treatment groups. No statistically significant difference
in the primary outcome was seen for ciprofloxacin versus no ciprofloxacin
(P = 0.15) or tamsulosin versus no tamsulosin (P > 0.2). Treatments also
did not differ significantly for any of the secondary outcomes. LIMITATIONS:
Treatment lasting longer than 6 weeks was not tested. Patients who had received
less pretreatment may have responded differently. CONCLUSION: Ciprofloxacin
and tamsulosin did not substantially reduce symptoms in men with long-standing
CP/CPPS who had at least moderate symptoms.
|
| |
|
Drug information |
|
| GENERIC NAME: tamsulosin
BRAND NAME: gneric Flomax
DRUG CLASS AND MECHANISM: Tamsulosin is a drug for the
treatment of men who are having difficulty urinating because of benign
prostatic hyperplasia (BPH). In men, the tube which carries urine from
the bladder to the penis (called the urethra) travels through the prostate
gland. As men get older, the prostate gland enlarges, and the muscle cells
within the prostate gland and the neck of the bladder (which control the
flow of urine) tighten. The combination of enlargement and tightening
of muscles compresses the urethra and obstructs the flow of urine. This
results in difficulty urinating and retention of urine within the bladder.
The tightening or contraction of the muscle cells is controlled by nerves.
One type of nerve, the alpha adrenergic nerves, cause the muscle cells
to tighten by releasing a chemical related to epinephrine (adrenalin).
Tamsulosin blocks the effects of this chemical on the muscle cells and
causes the muscles to relax. This results in a decrease in obstruction
to the flow of urine. There are other drugs which block alpha adrenergic
nerves throughout the body and which are used in treating diseases of
the heart and blood vessels, for example, prazosin (Minipress), terazosin
(Hytrin), and doxazosin (Cardura). Tamsulosin is more active against the
alpha adrenergic nerves of the prostate and bladder neck than these other
drugs and has a lesser effect on alpha adrenergic nerves elsewhere in
the body. For this reason, tamsulosin causes fewer side effects, especially
low blood pressure, than other alpha adrenergic blocking drugs. Moreover,
tamsulosin therapy can be started at the optimum dose whereas other alpha
adrenergic blocking drugs need to be started at low doses with the doses
slowly increased over time in order to minimize the side effects. Tamsulosin
was approved by the FDA in 1997.
PREPARATIONS: Capsules: 0.4mg.
STORAGE: Capsules should be stored at room temperature,
15-30 °C (59-86 °F).
PRESCRIBED FOR: Tamsulosin is used to treat men who
are having problems urinating because of BPH.
DOSING: Tamsulosin should be taken once daily after a meal. When taken
on an empty stomach, more of the medication is absorbed. This could cause
a greater effect and potentially a drop in blood pressure.
DRUG INTERACTIONS: There have been no drug interactions
described with tamsulosin. No important interactions were noted when tamsulosin
was used with atenolol (Tenormin), enalapril (Vasotec), and nifedipine
(Adalat; Procardia).
PREGNANCY: This medication is used only in men. However,
animal studies have not demonstrated any risk to the fetus. There are
no adequate studies in pregnant women.
NURSING MOTHERS: This medication is used only in men.
It is not known if tamsulosin is secreted into breast milk.
SIDE EFFECTS: Tamsulosin is generally well tolerated.
Occasionally, tamsulosin can cause a drop in blood pressure, rarely resulting
in dizziness or fainting. Other reported side effects include headache,
dizziness, nasal congestion, and palpitations. Glossary content Copyright
© 1996-2002 MedicineNet, Inc. All rights reserved.
Caution! Before starting
to take this medicine, it is vital that you should consult your doctor!
Do not use it on your own initiative, without medical advice.
|
| |
|
Order now ! |
|
Dosage |
Packing |
Price |
Pay now |
0.4 mg |
30 tabs |
USD 57.00 |
|
0.4 mg |
60 tabs |
USD 0.00 |
|
0.4 mg |
90 tabs |
USD 0.00 |
|
|
|
| |
|  
|
|
